Christian Melander

TL;DR: Recent developments toward combination therapies for the treatment of multidrug-resistant bacterial infections are described, and the development of adjuvants that either directly target resistance mechanisms such as the inhibition of β-lactamase enzymes, or indirectly target resistance by interfering with bacterial signaling pathways such as two-component systems (TCSs).

TL;DR: A fragment of the potent HIV inhibitor TAK-779 was synthesized and conjugated to 2.0 nm diameter gold nanoparticles, and the (SDC-1721)-gold nanoparticle conjugates displayed activity comparable to that of Tak-779, suggesting that multivalent presentation of small molecules on gold nanoparticle surfaces can convert inactive drugs into potent therapeutics.

TL;DR: This review discuses the numerous approaches that have been applied to the discovery of lead small molecules that mediate biofilm development and highlights the development of small molecule that inhibit and/or disperse bacterial biofilms through non-microbicidal mechanisms.

TL;DR: The synergistic effect between a 2-aminoimidazole/triazole conjugate and antibiotics toward dispersing preestablished biofilms, culminating with a 3-orders-of-magnitude increase of biofilm dispersion toward Staphylococcus aureus biofilmms is reported.

TL;DR: Small molecule strategies to overcome resistance to β-lactam antibiotics include the development of β- lactamase inhibitors and compounds that interfere with the ability of the bacteria to sense an antibiotic threat and activate their resistance mechanisms.